Literature DB >> 35122609

A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.

Mayuri Shukla1, Prapimpun Wongchitrat2, Piyarat Govitrapong3,4.   

Abstract

Numerous challenges are confronted when it comes to the recognition of therapeutic agents for treating complex neurodegenerative diseases like Alzheimer's disease (AD). The perplexing pathogenicity of AD embodies cholinergic dysfunction, amyloid beta (Aβ) aggregation, neurofibrillary tangle formation, neuroinflammation, mitochondrial disruption along with vicious production of reactive oxygen species (ROS) generating oxidative stress. In this frame of reference, drugs with multi target components could prove more advantageous to counter complex pathological mechanisms that are responsible for AD progression. For as much as, medicinal plant based pharmaco-therapies are emerging as potential candidates for AD treatment keeping the efficacy and safety parameters in terms of toxicity and side effects into consideration. Huperzine A (Hup A) is a purified alkaloid compound extracted from a club moss called Huperzia serrata. Several studies have reported both cholinergic and non-cholinergic effects of this compound on AD with significant neuroprotective properties. The present review convenes cumulative demonstrations of neuroprotection provided by Hup A in in vitro, in vivo, and human studies in various pathologies. The underlying molecular mechanisms of its actions have also been discussed. However, more profound evidence would certainly promote the therapeutic implementation of this drug thus furnishing decisive insights into AD therapeutics and various other pathologies along with preventive and curative management.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alzheimer's disease; Amyloid beta; Cholinergic dysfunction; Huperzine A; Mitochondrial disruption; Neuroinflammation; Oxidative stress

Mesh:

Substances:

Year:  2022        PMID: 35122609     DOI: 10.1007/s11064-022-03530-2

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  139 in total

1.  Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD).

Authors:  M Ratia; L Giménez-Llort; P Camps; D Muñoz-Torrero; B Pérez; M V Clos; A Badia
Journal:  Neurodegener Dis       Date:  2012-05-24       Impact factor: 2.977

Review 2.  Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease.

Authors:  D L Bai; X C Tang; X C He
Journal:  Curr Med Chem       Date:  2000-03       Impact factor: 4.530

3.  Three Lycopodium alkaloids from Thai club mosses.

Authors:  Thanasan Nilsu; Wachirasak Thaisaeng; Wanlaya Thamnarak; Chatchakorn Eurtivong; Apiwan Jumraksa; Sakornrat Thorroad; Nisachon Khunnawutmanotham; Somsak Ruchirawat; Nopporn Thasana
Journal:  Phytochemistry       Date:  2018-09-17       Impact factor: 4.072

Review 4.  Serratene triterpenoids and their biological activities from Lycopodiaceae plants.

Authors:  Sasiwadee Boonya-Udtayan; Nopporn Thasana; Nongpanga Jarussophon; Somsak Ruchirawat
Journal:  Fitoterapia       Date:  2019-05-28       Impact factor: 2.882

5.  Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students.

Authors:  Q Q Sun; S S Xu; J L Pan; H M Guo; W Q Cao
Journal:  Zhongguo Yao Li Xue Bao       Date:  1999-07

6.  Squarrosine A and Pyrrolhuperzine A, New Lycopodium Alkaloids from Thai and Philippine Huperzia squarrosa.

Authors:  Thanasan Nilsu; Sakornrat Thorroad; Somsak Ruchirawat; Nopporn Thasana
Journal:  Planta Med       Date:  2016-05-18       Impact factor: 3.352

Review 7.  Neurogenesis and Alzheimer's disease: at the crossroads.

Authors:  Orly Lazarov; Robert A Marr
Journal:  Exp Neurol       Date:  2009-08-19       Impact factor: 5.330

Review 8.  Huperzine A from Huperzia species--an ethnopharmacolgical review.

Authors:  Xiaoqiang Ma; Changheng Tan; Dayuan Zhu; David R Gang; Peigen Xiao
Journal:  J Ethnopharmacol       Date:  2007-06-02       Impact factor: 4.360

Review 9.  Neuropathology of Alzheimer's disease.

Authors:  Daniel P Perl
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

10.  In Silico-Guided Rational Drug Design and Semi-synthesis of C(2)-Functionalized Huperzine A Derivatives as Acetylcholinesterase Inhibitors.

Authors:  Shisanupong Anukanon; Pornkanok Pongpamorn; Wareepat Tiyabhorn; Jaruwan Chatwichien; Worawat Niwetmarin; Richard B Sessions; Somsak Ruchirawat; Nopporn Thasana
Journal:  ACS Omega       Date:  2021-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.